August 23, 2016 5:39pm

… As sector feels August’s disinterest

 

This can be attributed to the sector itself – skepticism and the lack of news

... Risk and performance reflect nomadic volume and fluctuating indicators

 

Pre-open indication’s tally: 5 hits (FATE, JUNO, KOOL, PSTI and RGNX) and 0 miss

 

I answer one question; in which company should investors put, keep and commit their money!

 

Do you care what happened today, you should … because it has implications to Wednesday's sector activity?   Where has today’s market gone – subscribe and find out. 

 

 

 

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

U.S. stocks closed on Tuesday, with materials gaining about 1 percent, as investors looked ahead to Federal Reserve Chair Janet Yellen's speech at the end of the week.

The NASDAQ closed UP +15.48 or +0.30% to 5,260.08 and the DOW closed UP +17.88 or +0.10% to 18,547.30.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:    

  • The open was positive with an A/DL of 26/15 and 2 flats;
  • The mid-day turned negative  with an A/DL of 19/23 and 1 flat;
  • The closing bell was negative with A/DL of 14/28 and 1 flat;

 

 

Henry’omics:

The stem, cell, gene and regenerative therapy (SCGT&RT) sector opened positive turned negative at the mid-day with the sector closing negative.

  • Stocks have recently traded in a very tight range, amid low volume and volatility.

Volume is still low and volatility is higher.

  • I’m still holding on to “some” equities, recommending selling others and sticking my head in the sand until after Labor Day!

 

Call me cantankerous, contrarian or even a curmudgeon but at the least I get it right and investors make money!

 

 

Today’s Bottom Line:

I'm not surprised the sector got creamed; I am surprised it shot down that much!

 

 

Pre-open indication’s tally:  5 hits and 0 miss:

  • Cesca Therapeutics (KOOL) closed DOWN -$0.45 – hit;
  • Juno Therapeutics (JUNO) closed DOWN -$0.04 – hit;
  • Fate Therapeutics FATE) closed DOWN -$0.05 – hit;
  • Pluristem (PSTI) closed DOWN -$0.00 – hit;
  • Regenxbio (RGNX) closed DOWN -$0.34 – hit;

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Tuesday traded 12.19;
  • Monday traded 12.6;
  • Friday traded near 11.6;
  • Thursday trade near 11.6;
  • Wednesday traded 12.5;
  • Last Tuesday traded 12.5;

 

 

Decliners:

  • Northwest Bio (NWBO) -16.53%;
  • Cesca Therapeutics (KOOL) -9.57% after Monday’s+12.98% after Friday’s +7.22%;
  • VistaGen (VTGN) -7.14%;
  • uniQure (QURE) -4.95% after Monday’s +8.16%;
  • Biostage (BSTG) -3% after Monday’s -6.73%;

 

Advancers:

  • Opexa (OPXA) +3.61% after Monday’s +5.48% ;
  • Adverum (ADVM) +5.42%;
  • ReNeuron (RENE.L) +4.76% after Monday’s -8.85% ;
  • Capricor (CAPR) +1.67%;
  • Vericel (VCEL) +3.96%

 

Flat:

  • Asterias Biotherapeutics (NYSEMKT: AST) at $2.86;

                                                                                                                                       

                                                                                                  

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.